Brief: Actinium Announces Positive Pivotal Phase 3 Sierra Trial Results
12/06/2023 12:00
June 12 (Reuters) - Actinium Pharmaceuticals Inc
ATNM.A :
* ACTINIUM ANNOUNCES POSITIVE PIVOTAL PHASE 3 SIERRA TRIAL
RESULTS
IN AN ORAL PRESENTATION AT THE EHA 2023 CONGRESS
* ACTINIUM PHARMACEUTICALS - SIERRA RESULTS DEMONSTRATE
UNPRECEDENTED BONE MARROW TRANSPLANT ACCESS AND OUTCOMES WITH
IOMAB-B
* ACTINIUM PHARMACEUTICALS INC - BLA FILING FOR IOMAB-B
EXPECTED
BY YEAR END 2023 BASED ON POSITIVE PIVOTAL PHASE 3 SIERRA
RESULTS
Source text for Eikon: ID:nPn9MwbhDa
Further company coverage: ATNM.A
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities